Cargando…

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis and considered to be a less severe condition than rheumatoid arthritis. PsA patients have been treated for a long time with a number of different agents, from non-steroidal anti-inflammatory drugs to one or more disease-modifying antirheu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montepaone, Monica, Lubrano, Ennio, Carboni, Alessia, Spadaro, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045109/ https://www.ncbi.nlm.nih.gov/pubmed/27790030 http://dx.doi.org/10.2147/OARRR.S56048

Ejemplares similares

Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies
por: Lubrano, Ennio, et al.
Publicado: (2014)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2023)

Corticosteroid injection treatment for dactylitis in psoriatic arthritis
por: Carriero, Antonio, et al.
Publicado: (2021)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

The “Climb” Towards Minimal Disease Activity in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2021)

The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study
por: Scarpa, Raffaele, et al.
Publicado: (2011)

Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis
por: Gediz, Fusun, et al.
Publicado: (2021)

Profile of certolizumab and its potential in the treatment of psoriatic arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2013)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
por: Lubrano, Ennio, et al.
Publicado: (2019)

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
por: Rahman, Proton, et al.
Publicado: (2016)

Simple clinical indicators for early psoriatic arthritis detection
por: Caso, Francesco, et al.
Publicado: (2014)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
por: Scriffignano, Silvia, et al.
Publicado: (2023)

Clinical Characteristics of Potential “Difficult-to-treat” Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort
por: Perrotta, Fabio Massimo, et al.
Publicado: (2022)

Psoriatic Arthritis in Males and Females: Differences and Similarities
por: Lubrano, Ennio, et al.
Publicado: (2023)

New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review
por: Perrotta, Fabio Massimo, et al.
Publicado: (2021)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
por: Lubrano, Ennio, et al.
Publicado: (2022)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
por: Tillett, William, et al.
Publicado: (2023)

Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab
por: Kim, Jeong Soo, et al.
Publicado: (2018)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Ultrasonographic Evaluation of Entheseal Fibrocartilage in Patients with Psoriatic Arthritis, Athletes and Healthy Controls: A Comparison Study
por: Perrotta, Fabio Massimo, et al.
Publicado: (2023)

Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study
por: Scriffignano, Silvia, et al.
Publicado: (2022)

Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study
por: Lubrano, Ennio, et al.
Publicado: (2020)

Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices
por: Lubrano, Ennio, et al.
Publicado: (2020)

Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
por: Lubrano, Ennio, et al.
Publicado: (2023)

Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
por: Leu, Jocelyn H., et al.
Publicado: (2022)

Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study
por: Wendler, Jörg, et al.
Publicado: (2022)

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
por: Tuskey, Anne, et al.
Publicado: (2014)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
por: Coates, Laura C., et al.
Publicado: (2022)

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
por: Ghosh, Subrata, et al.
Publicado: (2019)

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
por: Van Kuijk, Arno W R, et al.
Publicado: (2023)

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
por: Olivieri, I., et al.
Publicado: (2008)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
por: Ghosh, Subrata, et al.
Publicado: (2019)

Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b7t9tg12l2j0culhpq05l2lqcq